Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 8/20 | 0.74 |
| ▸ | HTR2C | P28335 | 4/20 | 0.74 |
| ▸ | HTR7 | P34969 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenharmane SCHEMBL9695673 | 0.86 | GRIN2B (1.00) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL764540 | 0.85 | HTR2A (1.00) | GRIN2BHTR2AHTR2CMAPKAPK2 | |
| Fenharmane SCHEMBL9696484 | 0.85 | GRIN2B (0.97) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL11216720 | 0.81 | GRIN2B (0.64) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL10857696 | 0.81 | GRIN2B (0.67) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL10924004 | 0.80 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL5532807 | 0.80 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL8322968 | 0.80 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL21883968 | 0.80 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CYP3A4 | |
| SCHEMBL29756361 | 0.80 | GRIN2B (0.70) | GRIN2BHTR2AHTR2CHTR7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272572-A1 | ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN | PURDUE RESEARCH FOUNDATION | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272572-A1 | ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN | ADCY1, ADCY2, ADCY5 | GRIN2B 536/4885HTR2A 1789/4885HTR2C 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.